View Past PerformanceEcho IQ バランスシートの健全性財務の健全性 基準チェック /66Echo IQの総株主資本はA$17.3M 、総負債はA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれA$18.0MとA$718.6Kです。主要情報0%負債資本比率AU$0負債インタレスト・カバレッジ・レシオn/a現金AU$11.21mエクイティAU$17.27m負債合計AU$718.61k総資産AU$17.99m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 25Echo IQ Limited Completes its Clinical Validation for its Heart Failure Clinical Decision Support Software in Collaboration with the Mayo Clinic PlatformEcho IQ Limited announced that it has completed its clinical validation for its heart failure clinical decision support software ("EchoSolv HF") in collaboration with the Mayo Clinic Platform ("MCP"), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software. The clinical validation was designed to evaluate the EchoSolv HF model's ability to detect heart failure on an independent dataset of ~17,000 individual echocardiogram studies. In a major milestone, the primary endpoint of the clinical validation has been met, with results exceeding expectations. The study results show that EchoSolv HF demonstrated outstanding performance in identifying patients with heart failure, achieving a sensitivity of 99.5%. Likewise, the model was accurate in identifying patient that did not have heart failure, achieving a specificity of 91.0%. Completion of the clinical validation marks the final clinical requirement prior to a formal submission for clearance by the US Food & Drug Administration ("FDA"). Echo IQ is now in the process of completing its formal submission to advance the clearance of EchoSolv HF via the FDA's 510(k) regulatory pathway. The Company expects to lodge this submission in the coming weeks. FDA clearance of the solution would allow for EchoSolv HF to be marketed to and used by healthcare professionals in the USA as a clinical decision support software to aid in the detection of heart failure. Heart failure is the leading cause for rehospitalisation in the US and accounts for 17% of all healthcare expenditure in the country. It is now estimated that one in four Americans will develop heart failure in their lifetime. Upon potential FDA clearance of the solution, the Company intends to leverage its existing footprint in the US market to drive uptake of EchoSolv HF.お知らせ • Nov 13Echo Iq Highlights Market Potential for Echosolv as Following Presentation of New Data for Severe Aortic Stenosis (As) Presented At Aha Scientific Sessions 2025Echo IQ announced that overwhelmingly convincing data from two recent studies have highlighted the significant gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS), and potential for EchoSolv AS to drive improved patient outcomes. The results from both studies were presented separately at the American Heart Association (AHA) Scientific Sessions 2025, which was held in New Orleans, Louisiana. A key takeaway from the study that reviewed echocardiograms for more than 1.2 million patients is that the 'watchful waiting' strategy for moderate-to-severe AS cases is failing many of these patients. In addition, the insights from the results that show how EchoSolv AS was able to identify the severe AS phenotype more accurately than cardiologists, particularly in some subtypes of AS. This study was of particular interest as it showed clearly that the company have work to do in accurately diagnosing women with aortic stenosis and the company are optimistic with the performance of EchoSolv AS to improve the gender equity. Study titled, "Accuracy of cardiologist reporting of severe aortic stenosis vs decision-support artificial intelligence and its impact on clinical management" presented by Dr. Vikas Bhat, University of Notre Dame Australia, this investigator-initiated study compared traditional cardiologist reporting with EchoSolv™?, an AI-powered clinical decision support system. Findings from 30,878 echocardiograms revealed: EchoSolv outperformed cardiologists in identifying severe AS phenotypes, particularly in women and low- gradient cases. Findings underscore the need for policy and clinical practice changes to address treatment gaps and improve survival. This study was funded by an IIS grant from Edwards LifeScience. The funders played no part in the data curation/analysis /preparation of these data. EchoSolv AS is poised to change this paradigm by enabling more precise and consistent identification of high-risk AS patients, thereby supporting clinicians in making informed, timely decisions regarding intervention. Globally, AS is a widespread but frequently underdiagnosed condition, primarily caused by calcification of the aortic valve, which serves as a critical gateway to the heart. Failure to diagnose AS in a timely manner can lead to missed opportunities for lifesaving interventions, such as valve replacement surgery. EchoSolv AS has undergone rigorous validation, including FDA Clearance, through extensive testing across both the United States and Australia, demonstrating the utility of aiding in the accurate diagnosis of patients with aortic stenosis. NEDA principal investigator, Professor David Playford, the senior author for both studies, said: " These studies confirm previous reports in two ways. First, reaffirm that moderate and severe aortic stenosis is a lifethreatening condition that causes significant health service utilization, heart failure hospitalizations and premium mortality. Second, artificial intelligence is capable of outperforming cardiologists in the identification of the set of abnormalities that happen when aortic stenosis progresses toward the severe state. These two findings, taken together, reinforce that EchoSolv AS AI should be considered as a routine option during echocardiographic reporting. Authorised for release by the Board of Directors of Echo IQ Limited.お知らせ • Sep 30Echo IQ Limited, Annual General Meeting, Nov 18, 2025Echo IQ Limited, Annual General Meeting, Nov 18, 2025.財務状況分析短期負債: PL4の 短期資産 ( A$13.5M ) が 短期負債 ( A$718.6K ) を超えています。長期負債: PL4には長期負債はありません。デット・ツー・エクイティの歴史と分析負債レベル: PL4は負債がありません。負債の削減: PL4 5 年前には負債がありませんでした。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: PL4は、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: PL4は、フリー キャッシュ フローが毎年28.1 % の歴史的率で減少し続ける場合、 1.1年間十分なキャッシュ ランウェイを有しています。健全な企業の発掘7D1Y7D1Y7D1YSoftware 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 20:20終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Echo IQ Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Rahul TiwariEastCoast ResearchIain WilkieMorgans Financial LimitedThomas GodfreyOrd Minnett Limited
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 25Echo IQ Limited Completes its Clinical Validation for its Heart Failure Clinical Decision Support Software in Collaboration with the Mayo Clinic PlatformEcho IQ Limited announced that it has completed its clinical validation for its heart failure clinical decision support software ("EchoSolv HF") in collaboration with the Mayo Clinic Platform ("MCP"), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software. The clinical validation was designed to evaluate the EchoSolv HF model's ability to detect heart failure on an independent dataset of ~17,000 individual echocardiogram studies. In a major milestone, the primary endpoint of the clinical validation has been met, with results exceeding expectations. The study results show that EchoSolv HF demonstrated outstanding performance in identifying patients with heart failure, achieving a sensitivity of 99.5%. Likewise, the model was accurate in identifying patient that did not have heart failure, achieving a specificity of 91.0%. Completion of the clinical validation marks the final clinical requirement prior to a formal submission for clearance by the US Food & Drug Administration ("FDA"). Echo IQ is now in the process of completing its formal submission to advance the clearance of EchoSolv HF via the FDA's 510(k) regulatory pathway. The Company expects to lodge this submission in the coming weeks. FDA clearance of the solution would allow for EchoSolv HF to be marketed to and used by healthcare professionals in the USA as a clinical decision support software to aid in the detection of heart failure. Heart failure is the leading cause for rehospitalisation in the US and accounts for 17% of all healthcare expenditure in the country. It is now estimated that one in four Americans will develop heart failure in their lifetime. Upon potential FDA clearance of the solution, the Company intends to leverage its existing footprint in the US market to drive uptake of EchoSolv HF.
お知らせ • Nov 13Echo Iq Highlights Market Potential for Echosolv as Following Presentation of New Data for Severe Aortic Stenosis (As) Presented At Aha Scientific Sessions 2025Echo IQ announced that overwhelmingly convincing data from two recent studies have highlighted the significant gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS), and potential for EchoSolv AS to drive improved patient outcomes. The results from both studies were presented separately at the American Heart Association (AHA) Scientific Sessions 2025, which was held in New Orleans, Louisiana. A key takeaway from the study that reviewed echocardiograms for more than 1.2 million patients is that the 'watchful waiting' strategy for moderate-to-severe AS cases is failing many of these patients. In addition, the insights from the results that show how EchoSolv AS was able to identify the severe AS phenotype more accurately than cardiologists, particularly in some subtypes of AS. This study was of particular interest as it showed clearly that the company have work to do in accurately diagnosing women with aortic stenosis and the company are optimistic with the performance of EchoSolv AS to improve the gender equity. Study titled, "Accuracy of cardiologist reporting of severe aortic stenosis vs decision-support artificial intelligence and its impact on clinical management" presented by Dr. Vikas Bhat, University of Notre Dame Australia, this investigator-initiated study compared traditional cardiologist reporting with EchoSolv™?, an AI-powered clinical decision support system. Findings from 30,878 echocardiograms revealed: EchoSolv outperformed cardiologists in identifying severe AS phenotypes, particularly in women and low- gradient cases. Findings underscore the need for policy and clinical practice changes to address treatment gaps and improve survival. This study was funded by an IIS grant from Edwards LifeScience. The funders played no part in the data curation/analysis /preparation of these data. EchoSolv AS is poised to change this paradigm by enabling more precise and consistent identification of high-risk AS patients, thereby supporting clinicians in making informed, timely decisions regarding intervention. Globally, AS is a widespread but frequently underdiagnosed condition, primarily caused by calcification of the aortic valve, which serves as a critical gateway to the heart. Failure to diagnose AS in a timely manner can lead to missed opportunities for lifesaving interventions, such as valve replacement surgery. EchoSolv AS has undergone rigorous validation, including FDA Clearance, through extensive testing across both the United States and Australia, demonstrating the utility of aiding in the accurate diagnosis of patients with aortic stenosis. NEDA principal investigator, Professor David Playford, the senior author for both studies, said: " These studies confirm previous reports in two ways. First, reaffirm that moderate and severe aortic stenosis is a lifethreatening condition that causes significant health service utilization, heart failure hospitalizations and premium mortality. Second, artificial intelligence is capable of outperforming cardiologists in the identification of the set of abnormalities that happen when aortic stenosis progresses toward the severe state. These two findings, taken together, reinforce that EchoSolv AS AI should be considered as a routine option during echocardiographic reporting. Authorised for release by the Board of Directors of Echo IQ Limited.
お知らせ • Sep 30Echo IQ Limited, Annual General Meeting, Nov 18, 2025Echo IQ Limited, Annual General Meeting, Nov 18, 2025.